康弘药业
(002773)
| 流通市值：197.49亿 | | | 总市值：264.92亿 |
| 流通股本：6.87亿 | | | 总股本：9.21亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,198,743,422.58 | 4,452,657,799 | 3,411,293,193.61 | 2,294,131,650.05 |
| 营业收入 | 1,198,743,422.58 | 4,452,657,799 | 3,411,293,193.61 | 2,294,131,650.05 |
| 二、营业总成本 | 749,205,765.44 | 3,160,129,826.79 | 2,311,766,338.66 | 1,512,181,562.51 |
| 营业成本 | 125,209,183.97 | 466,462,782.31 | 345,306,027.89 | 234,071,095.54 |
| 税金及附加 | 13,318,519.54 | 58,965,198.86 | 42,565,790.28 | 30,927,987.79 |
| 销售费用 | 423,081,043.08 | 1,646,426,383.28 | 1,287,805,702.52 | 857,730,094.38 |
| 管理费用 | 108,784,211.05 | 470,904,033.78 | 340,307,482.38 | 228,633,284.86 |
| 研发费用 | 94,301,139.91 | 579,712,150.27 | 342,158,088.75 | 192,874,128.61 |
| 财务费用 | -15,488,332.11 | -62,340,721.71 | -46,376,753.16 | -32,055,028.67 |
| 其中:利息收入 | 15,510,768.84 | 62,906,737.85 | 47,008,183.2 | 31,191,032.58 |
| 加:公允价值变动收益 | -963,000 | -1,056,000 | -1,387,200 | -969,600 |
| 加:投资收益 | -134,361.58 | 47,277,710.26 | 20,318,174.16 | 19,266,908.69 |
| 资产处置收益 | 643.36 | 14,202.59 | 14,591.48 | 13,972.01 |
| 资产减值损失(新) | 540,911.92 | -2,777,635.36 | -746,316.13 | -746,316.13 |
| 信用减值损失(新) | 10,057.98 | 833,746.07 | -1,983,250.5 | -2,754,908.7 |
| 其他收益 | 16,585,313.78 | 44,509,870.72 | 32,979,760.34 | 23,769,529.72 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 465,577,222.6 | 1,381,329,866.49 | 1,148,722,614.3 | 820,529,673.13 |
| 加:营业外收入 | 428,356.66 | 5,380,741.6 | 2,339,734.71 | 1,013,868.69 |
| 减:营业外支出 | 3,200,443.88 | 34,173,640.96 | 12,891,848.86 | 4,245,643.66 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 462,805,135.38 | 1,352,536,967.13 | 1,138,170,500.15 | 817,297,898.16 |
| 减:所得税费用 | 66,180,368.91 | 175,528,898.11 | 173,280,670.12 | 130,761,803.92 |
| 六、净利润 | 396,624,766.47 | 1,177,008,069.02 | 964,889,830.03 | 686,536,094.24 |
| 持续经营净利润 | 396,624,766.47 | 1,177,008,069.02 | 964,889,830.03 | 686,536,094.24 |
| 归属于母公司股东的净利润 | 400,017,678.69 | 1,191,230,760.93 | 973,711,578.04 | 692,220,039.94 |
| 少数股东损益 | -3,392,912.22 | -14,222,691.91 | -8,821,748.01 | -5,683,945.7 |
| (一)基本每股收益 | 0.43 | 1.3 | 1.06 | 0.75 |
| (二)稀释每股收益 | 0.43 | 1.3 | 1.06 | 0.75 |
| 八、其他综合收益 | -518,692.27 | 13,717.61 | -148,087.22 | -470,338.38 |
| 归属于母公司股东的其他综合收益 | -518,692.27 | 13,717.61 | -148,087.22 | -470,338.38 |
| 九、综合收益总额 | 396,106,074.2 | 1,177,021,786.63 | 964,741,742.81 | 686,065,755.86 |
| 归属于母公司股东的综合收益总额 | 399,498,986.42 | 1,191,244,478.54 | 973,563,490.82 | 691,749,701.56 |
| 归属于少数股东的综合收益总额 | -3,392,912.22 | -14,222,691.91 | -8,821,748.01 | -5,683,945.7 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |